Low Performance of Sinovac Vaccine Particularly With Belatacept Therapy in a Study With Different Types of COVID-19 Vaccines in Transplanted Patients.
Journal
Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
08
11
2022
revised:
30
01
2023
accepted:
19
02
2023
medline:
1
5
2023
pubmed:
31
3
2023
entrez:
30
3
2023
Statut:
ppublish
Résumé
The huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is crucial to understand the performance of each type of available vaccine. In our study, the antibody titer was measured, and the presence of antibodies against SARS-CoV-2 was evaluated after 90 days of immunization; furthermore, the differences between hybrid immunity, immunity by vaccination, and immunosuppressant type were identified. As a result, of the patients included in this study (n = 160), 53% showed antibodies against SARS-CoV-2 90 days after the first dose in patients who had completed the vaccination schedule. Antibody titers were higher in patients with hybrid immunity, and the proportion of nonresponsive patients was higher among those who received the immunosuppressant belatacept in their post-transplant regimen (P = .01). Only 15% of patients treated with this medicine seroconverted and patients vaccinated with CoronaVac and treated with belatacept showed no response. In conclusion, a reduced response to vaccines against SARS-CoV-2 was identified in the transplant population, and this response varied with the type of vaccine administered and the immunosuppressive treatment.
Identifiants
pubmed: 36997378
pii: S0041-1345(23)00069-6
doi: 10.1016/j.transproceed.2023.02.034
pmc: PMC9974356
pii:
doi:
Substances chimiques
Abatacept
7D0YB67S97
Antibodies
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunosuppressive Agents
0
sinovac COVID-19 vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
500-507Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Références
Transpl Immunol. 2019 Apr;53:51-60
pubmed: 30664927
Transplantation. 2021 Nov 1;105(11):e259-e260
pubmed: 34387243
Am J Transplant. 2022 Mar;22(3):813-822
pubmed: 34657386
Transplantation. 2022 Apr 1;106(4):821-834
pubmed: 34753894
Vaccines (Basel). 2022 Feb 24;10(3):
pubmed: 35334985
Transplant Proc. 2021 May;53(4):1237-1244
pubmed: 33558085
Am J Transplant. 2021 Aug;21(8):2913-2915
pubmed: 33864722
Transplantation. 2021 Sep 1;105(9):2119-2123
pubmed: 34028386
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
Kidney Int. 2021 Jun;99(6):1487-1489
pubmed: 33775674
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
N Engl J Med. 2022 Mar 31;386(13):1221-1229
pubmed: 35172072
Transplantation. 2021 Nov 1;105(11):e226-e233
pubmed: 34381004
Clin Microbiol Infect. 2021 Aug;27(8):1173.e1-1173.e4
pubmed: 33957273
N Engl J Med. 2020 Jun 18;382(25):2475-2477
pubmed: 32329975
Am J Transplant. 2021 Dec;21(12):3980-3989
pubmed: 34347934
N Engl J Med. 2022 Feb 17;386(7):698-700
pubmed: 35021005
Am J Transplant. 2021 Aug;21(8):2727-2739
pubmed: 34036720
Transplantation. 2021 Sep 1;105(9):e94-e95
pubmed: 33831941
Transplantation. 2022 Apr 1;106(4):842-852
pubmed: 34999659
Am J Transplant. 2021 Aug;21(8):2919-2921
pubmed: 34058052
Clin Infect Dis. 2022 Aug 24;75(1):e594-e602
pubmed: 35255140
J Med Virol. 2022 Jul;94(7):3176-3183
pubmed: 35277975
Transpl Infect Dis. 2021 Dec;23(6):e13740
pubmed: 34606134
Kidney Int. 2021 Jun;99(6):1498-1500
pubmed: 33887315
Clin Transplant. 2022 Apr;36(4):e14585
pubmed: 34997797
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343